Equity Profile

CLDX

Celldex Therapeutics, Inc.

Health CareBiotechnology$3.0B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Celldex Therapeutics, Inc. (CLDX) is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors will closely watch this quarter.

N/A

Revenue Growth

Although revenue estimates are not available, any growth or decline in revenue can significantly impact investor sentiment.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CLDX Q2-2026 Earnings Preview

Context

Company Snapshot

Celldex Therapeutics, Inc. (CLDX) is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases. With a market cap of $3 billion, it operates in the health care sector, where advancements in biotechnology are crucial for improving patient outcomes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-3.75%

Avg Stock Reaction

+3.90%

Last Quarter Recap

In Q1-2026, Celldex reported an EPS of -$1.18, which was worse than the expected -$1.10, leading to a stock drop of 3.11% the next day. The company continues to focus on its pipeline of therapies, but specific revenue figures were not disclosed.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given the company's focus on innovative therapies. However, the recent trend of missing EPS estimates raises concerns about future performance.

Bull Case

If Celldex can show improved clinical trial results or unexpected revenue growth, it could lead to a positive market reaction and increased investor confidence.

Bear Case

On the other hand, continued losses and lack of clear guidance could lead to further declines in stock price, especially if the company fails to meet expectations.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to analyst expectations?

The EPS figure will be critical in assessing the company's profitability and could significantly influence stock movement.

Are there any updates on ongoing clinical trials and their expected timelines?

Investors will closely monitor trial updates as they can impact the company's future revenue potential and overall market confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be overly focused on recent EPS misses and not fully accounting for potential positive developments in clinical trials that could drive future revenue.

Supporting Evidence

Options are pricing a 23.62% move, indicating that the market expects significant volatility, which may not align with the company's actual performance.

The average historical move of 5.59% suggests that the current options pricing may be inflated compared to past performance.

Key Risk

If the company provides unexpectedly positive updates on clinical trials, it could shift sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is crucial as it follows a trend of missed EPS estimates, and investors are looking for signs of recovery or continued decline.

Bull Confirmed If

A positive EPS surprise of at least 10% or better, alongside promising clinical trial updates, would confirm the bull case.

Bear Confirmed If

An EPS miss greater than 10% or negative updates on clinical trials would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±23.62%

Historical Avg

±5.6%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty or anticipation around the earnings report.

Options are pricing ±23.6% while CLDX has averaged ±5.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

33.3%

Calls (1K)P/C Ratio: 1.00Puts (600)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 14 of 29 (48%)

This setup has occurred 30 times across Health Care in the last 2 years. 14 of 29 faded and 15 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.7%, with a raw directional average of -1.4% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Celldex beats EPS expectations, history suggests a potential stock increase of around 2.01%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction, reflecting ongoing investor caution.

Miss

If the company misses EPS estimates again, the average historical reaction suggests a decline of about 5.80%, indicating heightened concern among investors.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific details on the outcomes of ongoing clinical trials.
2Guidance on future revenue expectations and product pipeline developments.
3Management's commentary on cost management and operational efficiency.
4Updates on partnerships or collaborations that could enhance growth prospects.
5Insights into market conditions and competitive landscape affecting the business.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Celldex Therapeutics, Inc. (CLDX) is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors will closely watch this quarter.

N/A

Revenue Growth

Although revenue estimates are not available, any growth or decline in revenue can significantly impact investor sentiment.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CLDX Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-3.75%

Avg Stock Reaction

+3.90%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Celldex can show improved clinical trial results or unexpected revenue growth, it could lead to a positive market reaction and increased investor confidence.

Bear Case

On the other hand, continued losses and lack of clear guidance could lead to further declines in stock price, especially if the company fails to meet expectations.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be for Q2-2026, and how does it compare to analyst expectations?

The EPS figure will be critical in assessing the company's profitability and could significantly influence stock movement.

Are there any updates on ongoing clinical trials and their expected timelines?

Investors will closely monitor trial updates as they can impact the company's future revenue potential and overall market confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be overly focused on recent EPS misses and not fully accounting for potential positive developments in clinical trials that could drive future revenue.

Supporting Evidence

Options are pricing a 23.62% move, indicating that the market expects significant volatility, which may not align with the company's actual performance.

The average historical move of 5.59% suggests that the current options pricing may be inflated compared to past performance.

Key Risk

If the company provides unexpectedly positive updates on clinical trials, it could shift sentiment dramatically.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is crucial as it follows a trend of missed EPS estimates, and investors are looking for signs of recovery or continued decline.

Bull Confirmed If

A positive EPS surprise of at least 10% or better, alongside promising clinical trial updates, would confirm the bull case.

Bear Confirmed If

An EPS miss greater than 10% or negative updates on clinical trials would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±23.62%

Historical Avg

±5.6%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty or anticipation around the earnings report.

Options are pricing ±23.6% while CLDX has averaged ±5.6% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

33.3%

Calls (1K)P/C Ratio: 1.00Puts (600)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss + options pricing rich setup in Health Care

n=30

Fade rate: 14 of 29 (48%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Celldex beats EPS expectations, history suggests a potential stock increase of around 2.01%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction, reflecting ongoing investor caution.

Miss

If the company misses EPS estimates again, the average historical reaction suggests a decline of about 5.80%, indicating heightened concern among investors.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any specific details on the outcomes of ongoing clinical trials.
2Guidance on future revenue expectations and product pipeline developments.
3Management's commentary on cost management and operational efficiency.
4Updates on partnerships or collaborations that could enhance growth prospects.
5Insights into market conditions and competitive landscape affecting the business.